Pfizer Ventures

Pfizer Ventures is the strategic corporate venture capital arm of Pfizer Inc., founded in 2004 and headquartered in New York. With a total capital commitment exceeding $900 million (including a $600 million top-up in 2021), it invests globally in innovative biopharmaceutical companies advancing breakthrough medicines with the potential to transform patients' lives. The fund backs private companies at all stages of development—with a strong bias toward early-stage opportunities—across Pfizer's core therapeutic areas: oncology, inflammation and immunology, rare disease, internal medicine, neuroscience, and vaccines. A guiding principle of the investment strategy is 'pipeline impact': Pfizer Ventures seeks companies developing potentially transformative therapeutics and enabling platform technologies (including drug discovery, delivery, diagnostics, and pharmaceutical services) that can enhance Pfizer's pipeline and shape the future of the industry. The team actively supports portfolio companies throughout their growth cycles, contributing strategic guidance, capital, and access to Pfizer's scientific expertise, and can lead or join syndicates while seeking board representation commensurate with investment size.